# Bladder cancer: symptoms, treatment and survival > Source: World Aid Network — https://worldaidnetwork.org/cancer/bladder-cancer > Last reviewed: 2026-06-19 ## In short Bladder cancer develops in the lining of the bladder, the organ that stores urine. Its most common — and most important — symptom is blood in the pee, which is usually painless and may come and go. Smoking is the biggest risk factor, causing around half of all cases. Blood in the urine is the warning sign that should always be checked. World Aid Network funds treatment for patients who cannot pay. ## At a glance - ~10,000: UK cases each year - Smoking (~50%): Biggest risk factor - Over 95% (Stage 1): Survival when caught early - Blood in the urine: Key sign ## What is bladder cancer? Bladder cancer develops in the lining of the bladder, the organ that stores urine. Its most common — and most important — symptom is blood in the pee, which is usually painless and may come and go. Smoking is the biggest risk factor, causing around half of all cases. Bladder cancer is the tenth most common cancer in the United Kingdom, with around 10,000 new diagnoses every year. It is approximately three times more common in men than in women, and more than 90% of cases occur in people over 55. Bladder cancer accounts for approximately 5,400 deaths per year in the UK. Smoking is responsible for approximately half of all bladder cancer cases — making it one of the most preventable cancers. The bladder's role as a reservoir for urine means it is exposed for prolonged periods to carcinogens excreted by the kidneys, including those derived from cigarette smoke and certain industrial chemicals. This guide answers the twenty most commonly searched questions about bladder cancer in the UK, drawing on NHS and WHO sources, and examines the inequality in bladder cancer care between the UK and low-income countries where specialist urology and oncology are scarce. The bladder is a hollow muscular organ in the pelvis that stores urine. Bladder cancer develops when cells lining the inside of the bladder wall grow abnormally. Approximately 90% of bladder cancers are urothelial carcinoma (formerly called transitional cell carcinoma — TCC), arising from the urothelium that lines the bladder. Less common types include squamous cell carcinoma (associated with chronic bladder irritation or schistosomiasis infection) and adenocarcinoma. Bladder cancers are classified by how deeply they have invaded the bladder wall. Non-muscle-invasive bladder cancer (NMIBC) — in which the cancer is confined to the inner lining (mucosa and submucosa) — accounts for approximately 75% of cases. Muscle-invasive bladder cancer (MIBC) — in which the cancer has grown into or through the muscle wall — accounts for approximately 25% and carries a worse prognosis. In the UK, the five-year survival rate for bladder cancer is approximately 55% across all stages. In low- and middle-income countries, survival is lower because specialist urology for TURBT and cystoscopy is concentrated in major hospitals, intravesical BCG is frequently out of stock, and radical cystectomy (a complex major operation) requires surgical and anaesthetic expertise that is unavailable in many settings. Notably, in parts of Africa and the Middle East, schistosomiasis (a parasitic infection) is a leading cause of the squamous cell type of bladder cancer, which is different from the urothelial carcinoma most common in the UK. This underscores how the drivers and presentation of bladder cancer differ by geography. World Aid Network funds cancer treatment — including bladder cancer — for poor patients through locally-licensed urologists and oncologists. Every donation funds a patient who would otherwise go without treatment. ## When should you see a doctor about bladder cancer? Most of these symptoms have a less serious cause — but it is always worth getting them checked. See a GP if you notice a new or persistent change. If you feel very unwell, contact NHS 111 or seek urgent help. Take a note of how long the symptom has lasted and whether it is getting worse. You do not need every sign on a list to book an appointment. This guide is general information from World Aid Network, not a diagnosis and not UK NHS care. Only a clinician can assess you. - Blood in your pee — even once, and even if it is painless - Needing to pee very often or very urgently - Pain or a burning feeling when you pee that is not a urine infection - Repeated urine infections that keep coming back ## What are symptoms: blood in urine and beyond? The classic presenting symptom of bladder cancer is haematuria — blood in the urine — which may be visible to the naked eye (frank haematuria, causing pink, red or brown urine) or detectable only on urine testing (microscopic haematuria). The NHS advises seeing a GP urgently if you notice blood in your urine even once, even if painless and even if it goes away on its own. Painless haematuria is a red-flag symptom. Other symptoms include: urinary urgency or frequency not explained by infection; pain during urination; or lower abdominal pain. Blood in the urine has many causes besides bladder cancer — including urinary tract infections, kidney stones and non-cancerous conditions — but should always be investigated promptly to rule out cancer. ## What are diagnosis and investigation? Investigation of haematuria follows a standardised NHS pathway. After urine dipstick testing and mid-stream urine culture to exclude infection, patients are referred for flexible cystoscopy — a procedure in which a thin flexible camera is passed through the urethra into the bladder under local anaesthetic to inspect the bladder lining directly. Any suspicious lesions are noted and a TURBT (transurethral resection of bladder tumour) is performed under general anaesthetic to remove the tumour and obtain tissue for pathological staging and grading. Imaging (CT urogram) is performed to assess the kidneys, ureters and upper urinary tract. For muscle-invasive disease, staging CT of the chest, abdomen and pelvis assesses for lymph node involvement and distant metastases. ## What treatment options are available? For non-muscle-invasive bladder cancer (NMIBC), TURBT is both diagnostic and therapeutic for low-risk disease. For intermediate- and high-risk NMIBC, a course of intravesical BCG (Bacillus Calmette-Guérin) instilled directly into the bladder after TURBT significantly reduces recurrence and progression risk. NMIBC is managed with regular cystoscopic surveillance because it has a high recurrence rate. For muscle-invasive bladder cancer (MIBC), the treatment options are radical cystectomy (surgical removal of the bladder, with urinary diversion) or radical radiotherapy with concurrent chemotherapy (chemoradiation). Neoadjuvant platinum-based chemotherapy (gemcitabine plus cisplatin) is offered before cystectomy to treat microscopic metastatic disease. Immunotherapy (pembrolizumab, atezolizumab) is used for metastatic bladder cancer after platinum chemotherapy. ## What are the key takeaways? The most important points on bladder cancer for patients, families and donors. - Bladder cancer affects around 10,000 people in the UK per year. Smoking is responsible for approximately half of all cases — making it one of the most preventable cancers. - Blood in the urine (haematuria) — even once, even if painless — is a red-flag symptom that the NHS advises investigating urgently via GP referral. - Non-muscle-invasive bladder cancer (75% of cases) is treated with TURBT and, for high-risk disease, intravesical BCG. It carries a high recurrence rate and requires long-term cystoscopic surveillance. - Muscle-invasive bladder cancer (25% of cases) is treated with radical cystectomy or radical chemoradiation, typically with neoadjuvant chemotherapy. - In low-income countries, bladder cancer treatment is severely limited by the absence of accessible cystoscopy, TURBT facilities, BCG supply and surgical expertise. ## What will a donation for bladder cancer treatment provide? A gift to World Aid Network's Cancer Emergency Appeal helps pay for diagnosis and treatment that a poor patient has been recommended but cannot afford. Typical partner costs start at £10 for tests and £50 for a chemotherapy session. Trustees direct gifts to the most urgent cases. This is treatment access, not laboratory research and not UK NHS care. Clinicians in partner hospitals decide the medical plan. We fund the bill in Pakistan, Indonesia and Malaysia. The Cancer Emergency Appeal funds all types of cancer. Trustees direct gifts to the most urgent hospital bills in Pakistan, Indonesia and Malaysia. - £10 — Diagnostic tests that help a partner oncologist confirm the next step - £25 — Cancer medication towards a treatment cycle a family cannot afford - £50 — One chemotherapy session for a patient who would otherwise be turned away - £100 — Surgical support or a fuller block of treatment costs ## How can I donate to help people with bladder cancer? Donate by card on this page or at worldaidnetwork.org/donate and choose the Cancer Emergency Appeal. World Aid Network is a UK CIO with Charity Commission registration in progress; Gift Aid applies once registration is granted. If you need UK support as a patient or relative, see a GP, NHS 111, Macmillan or the specialist UK charity for this cancer. We fund treatment overseas; we are not a UK helpline. ## How do you get blood in your urine checked? Blood in the urine — even once, and even if it is not painful — should be checked by a GP. It is the warning sign that finds many bladder and kidney cancers early. - Do not wait for it to happen again: One episode of blood in your pee is enough to book a GP appointment, even if it then looks clear. - Mention pain, clots or other symptoms: Tell the GP about pain in your side or back, a lump, weight loss, or needing to pee more often. - Ask about tests: A GP can dip-test urine, arrange blood tests and refer you for scans or a camera test of the bladder if needed. - Stop smoking if you can: Smoking is a major cause of bladder cancer. Stopping lowers future risk and helps recovery if cancer is found. ## Frequently asked questions ### What is bladder cancer? Bladder cancer is a malignant tumour of the bladder — the hollow organ that stores urine. Approximately 90% of cases are urothelial carcinoma, arising from the inner bladder lining. Around 10,000 people are diagnosed in the UK each year. It is three times more common in men than women and is strongly linked to smoking. ### What are the symptoms of bladder cancer? The most common symptom is haematuria — blood in the urine, which may be visible (pink, red or brown urine) or detected only on testing. The NHS advises seeing your GP urgently for any blood in the urine, even once and even if painless. Other symptoms include urinary urgency, frequency, pain when urinating or lower abdominal pain. ### How common is bladder cancer in the UK? Bladder cancer is the tenth most common cancer in the UK, with approximately 10,000 new diagnoses per year. It accounts for approximately 5,400 deaths annually. It is approximately three times more common in men than in women, and over 90% of cases occur in people aged 55 and over. ### What causes bladder cancer? Smoking is responsible for approximately 50% of bladder cancer cases in the UK — carcinogens from cigarette smoke are excreted in urine and accumulate in the bladder wall. Other causes include occupational exposure to aromatic amines (used in rubber, dye and textile industries), chronic bladder irritation, recurrent urinary tract infections, schistosomiasis (in endemic regions) and prior pelvic radiotherapy. ### Does smoking cause bladder cancer? Yes. Smoking is the single biggest risk factor for bladder cancer, responsible for approximately half of all cases in the UK. Chemicals from cigarette smoke are absorbed into the bloodstream, filtered by the kidneys and concentrated in the urine. The bladder's prolonged exposure to these carcinogens causes DNA damage to the urothelial lining. Stopping smoking significantly reduces future risk and also improves treatment outcomes for those diagnosed. ### How is bladder cancer diagnosed? Bladder cancer is diagnosed through flexible cystoscopy — a procedure in which a thin camera is passed through the urethra into the bladder under local anaesthetic. Any suspicious lesions are removed under general anaesthetic in a TURBT (transurethral resection of bladder tumour) operation, providing tissue for histological diagnosis and staging. A CT urogram images the kidneys and ureters. Urine cytology can detect high-grade cancer cells shed into urine. ### What is a cystoscopy? A cystoscopy is a procedure to examine the inside of the bladder and urethra using a cystoscope — a thin flexible or rigid tube with a camera. Flexible cystoscopy under local anaesthetic is used for diagnostic assessment and surveillance. Rigid cystoscopy under general anaesthetic is used for TURBT (tumour removal). NHS cystoscopy is a day-case procedure. It causes mild discomfort and temporary urinary symptoms; serious complications are rare. ### What are the stages of bladder cancer? Bladder cancer is staged from Stage 0 to Stage IV. Non-muscle-invasive disease (NMIBC) includes: Stage 0a (papillary tumours confined to the inner lining), Stage 0is (flat carcinoma in situ — CIS), and Stage I (invasion into the lamina propria but not muscle). Muscle-invasive disease (MIBC) includes Stage II (into the muscle), Stage III (through the muscle into perivesical fat) and Stage IV (spread to lymph nodes or distant organs). Stage determines treatment. ### What is the difference between non-muscle-invasive and muscle-invasive bladder cancer? Non-muscle-invasive bladder cancer (NMIBC, approximately 75% of cases) is confined to the inner layers of the bladder wall (mucosa and submucosa). It is treated primarily with TURBT and intravesical therapies; the bladder can usually be preserved. Muscle-invasive bladder cancer (MIBC, approximately 25% of cases) has grown into the bladder muscle wall, carrying a significantly higher risk of spreading to lymph nodes and distant organs and requiring radical treatment (cystectomy or radiotherapy). ### What is the treatment for bladder cancer? For NMIBC: TURBT to remove the tumour; single post-operative dose of intravesical mitomycin C for low-risk disease; a course of intravesical BCG (6-week induction plus maintenance) for high-risk NMIBC; long-term cystoscopic surveillance. For MIBC: neoadjuvant chemotherapy (gemcitabine plus cisplatin) followed by radical cystectomy, or radical chemoradiotherapy for bladder preservation. For metastatic disease: systemic chemotherapy (gemcitabine plus cisplatin/carboplatin) and immunotherapy (pembrolizumab, avelumab). ### What is a TURBT? TURBT (transurethral resection of bladder tumour) is a surgical procedure performed under general anaesthetic in which a resectoscope is passed through the urethra into the bladder and the tumour is resected (cut away) using an electrosurgical loop. TURBT serves dual purposes: it removes the tumour and provides tissue for pathological staging. For non-muscle-invasive bladder cancer, TURBT may be the definitive treatment. For muscle-invasive disease, TURBT confirms diagnosis before radical treatment. ### What is intravesical BCG therapy? BCG (Bacillus Calmette-Guérin) is an immunotherapy instilled directly into the bladder through a catheter after TURBT. Originally a tuberculosis vaccine, BCG stimulates a local immune response in the bladder lining that helps destroy remaining cancer cells and reduce recurrence and progression risk. The standard schedule is a 6-week induction course followed by maintenance instillations over 1–3 years. BCG is the most effective intravesical treatment for high-risk NMIBC, significantly reducing both recurrence and progression to muscle-invasive disease. ### What is a radical cystectomy? Radical cystectomy is the surgical removal of the entire bladder, typically with the prostate and seminal vesicles in men, or the uterus, ovaries and part of the vagina in women, together with pelvic lymph node clearance. It is the primary surgical treatment for muscle-invasive bladder cancer. Following cystectomy, urinary diversion is created — either an ileal conduit (urostomy bag), a continent pouch or an orthotopic neobladder (reconstruction using bowel). Robotic-assisted laparoscopic cystectomy is increasingly performed in the UK. ### What is the survival rate for bladder cancer? Five-year survival for bladder cancer in the UK is approximately 55% overall. For non-muscle-invasive disease (the majority), five-year survival is approximately 80–90% — the main risk is recurrence rather than death. For muscle-invasive disease (Stage II–III), five-year survival is approximately 50% with radical treatment. For Stage IV (metastatic) bladder cancer, five-year survival is approximately 15–20%, with improvements seen in patients responding to immunotherapy. ### Can bladder cancer be cured? Low-risk non-muscle-invasive bladder cancer is effectively managed with TURBT and surveillance, and many patients are cured. High-risk NMIBC managed with BCG achieves durable response in approximately 60–70% of patients. Muscle-invasive bladder cancer treated with radical cystectomy or chemoradiation achieves cure in approximately 50% of carefully selected patients. Metastatic bladder cancer is not currently curable, but immunotherapy has produced long-lasting responses in some patients. ### Is bladder cancer hereditary? The majority of bladder cancers are not hereditary. Inherited gene mutations are responsible for a small proportion of cases. Lynch syndrome — caused by inherited mismatch repair gene mutations — modestly increases bladder cancer risk. Family history of bladder cancer is a minor risk factor. However, bladder cancer's strong association with modifiable risk factors (smoking, occupational exposure) means that most cases arise from environmental rather than genetic causes. ### Does blood in urine always mean bladder cancer? No. Blood in the urine (haematuria) has many causes, most of which are not cancer. Common causes include: urinary tract infection; kidney stones; benign prostatic hyperplasia in men; vigorous exercise; certain medications; and non-cancerous kidney conditions. However, the NHS advises that all haematuria — even a single episode — should be investigated promptly by a GP, as bladder cancer cannot be excluded without cystoscopy. Bladder cancer is found in approximately 10–20% of patients referred with visible haematuria. ### What occupations increase bladder cancer risk? Occupational exposure to aromatic amines is the second largest risk factor for bladder cancer after smoking. Workers in the rubber, dye and textile industries have historically had elevated bladder cancer risk. Hairdressers (exposure to hair dye chemicals), painters, lorry drivers (diesel exhaust), aluminium workers and leather tanners are also at increased risk. The Health and Safety Executive (HSE) and occupational health services can advise on monitoring and risk reduction for workers in high-exposure industries. ### How often does bladder cancer come back? Non-muscle-invasive bladder cancer has a high recurrence rate — approximately 50–70% of patients will experience at least one recurrence within five years of TURBT. This is why long-term cystoscopic surveillance is essential for all NMIBC patients. The risk of progression to muscle-invasive disease depends on tumour grade and stage: low-grade disease carries a progression risk of approximately 5%; high-grade NMIBC (including CIS) carries a progression risk of 15–40% without BCG treatment. ### How does bladder cancer affect people in developing countries? In low- and middle-income countries, bladder cancer access to care is severely constrained by the scarcity of cystoscopy facilities, TURBT operating capacity, BCG supply and radical surgical expertise. In parts of Africa and the Middle East, schistosomiasis-related squamous cell bladder cancer is prevalent, often presenting at an advanced, inoperable stage. World Aid Network funds cancer treatment for poor patients through locally-licensed urologists and oncologists, helping to address this treatment inequality. ## How you can help World Aid Network funds cancer treatment for poor patients in Pakistan, Indonesia and Malaysia through locally licensed oncologists. Donate at https://worldaidnetwork.org/cancer/bladder-cancer or https://worldaidnetwork.org/donate?cause=cancer-treatment&appeal=cancer-emergency ## Sources - NHS — Cancer: https://www.nhs.uk/conditions/cancer/ - Cancer Research UK --- This is general information, not medical advice, published by World Aid Network. Always consult a qualified clinician about your own health.